Register Now
Why register?
 The leading web portal for pharmacy resources, news, education and careers May 6, 2016
Pharmacy Choice - News - Over-the-Counter Drugs - May 6, 2016

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 27     Next >>     Go To Page:

5/5/16 - AMERISOURCEBERGEN CORP - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10- K for the fiscal year ended September 30, 2015. We are one of the largest global pharmaceutical sourcing and
5/5/16 - adds Convenience, Safeguards and Privacy
In a recent study done by Consumer Reports National Research Center, it showcased that out of the 1,037 adults, more than a third of respondents have noticed an increase of up to $100 per prescription within a 12- month span. A study that took place in Raleigh, N.C. noticed the price of generic Cymbalta varied from store to store. For instance, the
5/4/16 - Golden Age Resources (GDAR) Enters the Highly Profitable Pharmaceutical Business with New Management and a Potential Licensing Deal with Biopharma Pravo Alpha
Licensing Deal to Add Six Prescription Products with over 20 Billion dollars in Potential market size to GDAR PipelineSan Diego, CA 05/04/2016 Golden Age Resources Inc., a leading acquisition and development company, announced today that it entered the highly profitable pharmaceutical business with the signing of a term sheet with Biopharma P
5/4/16 - In-Vitro Diagnostics (IVD) Market is Expected to Hit $81.35 Billion By 2022: Credence Research has Published New Research Report Title " Global In-Vitro Diagnostics Market- Growth, Share, Opportunities& Competitive Analysis, 2016 -2022". According to the latest report published by Credence Research, Inc. "Global In-vitro Diagnostics Market- Growth, Opportunities, Competitive Analysis, and Forecast, 2016- 2022," the in-vi
5/4/16 - Mylan profit drops after series of acquisitions [The Pittsburgh Tribune-Review]
May 03 The generic drug industry is under pressure, but Mylan NV CEO Heather Bresch said the company is positioned to deal with lower prices and investor concerns about slowing growth. Mylan shares are down about 40 percent from a high last summer when it was fighting off an unwanted acquisition bid from Teva Pharmaceutical Industries while attem
5/4/16 - Mylan profits skid; company names new CFO [Pittsburgh Post-Gazette]
May 03 Generic drug giant Mylan reported that first-quarter profits skidded 75 percent to $13.9 million from $56.6 million a year earlier on higher expenses. "We are off to a great start in 2016," CEO Heather Bresch said in a statement, reaffirming the company's full-year adjusted earnings guidance of $4.85 to $5.15 per share. Mylan announced in
5/3/16 - Genentech Highlights Personalized Medicines and Cancer Immunotherapies at 2016 American Society of Clinical Oncology (ASCO) Annual Meeting
Genentech, a member of the Roche Group today announced new results from 19 approved and investigational medicines will be presented during the American Society of Clinical Oncology Annual Meeting from June 3- 7 in Chicago. Genentech will be presenting data from the J-ALEX trial, an open-label, randomized Phase III study that compared Alecensa to cr
5/3/16 - Got Unused Meds? Here's What to Do
Unwanted drugs need to be properly disposed of to reduce the risk of abuse or accidental use, the U.S. Food and Drug Administration says. Or, ask your local trash or recycling services about medication disposal services and guidelines, the FDA suggests. Another option is to deliver unused medicines to collectors registered with the U.S. Drug Enforc
5/3/16 - Kitov Creates Pill for Safely Treating Osteoarthritis Pain and Hypertension
NEW YORK, NY/ ACCESSWIRE/ May 3, 2016/ Combining two existing generic drugs, a new, safer solution to osteoarthritis pain is found; Kitov's drug passed Phase III with stunning results;. This latter category is exciting because FDA approval is easier- clinical trials have already been done and safety issues solved. But not all pharma firms travel th
5/3/16 - Management's Discussion and Analysis of Financial Condition and Results of Operations
CVS Health Corporation, together with its subsidiaries, is a pharmacy innovation company helping people on their path to better health. Our Pharmacy Services business generates revenue from a full range of pharmacy benefit management solutions, including plan design and administration, formulary management, Medicare Part D services, mail order, spe
5/3/16 - The Diagnostics Reports Bundle includes the following TriMark Publications reports at a 15% discount off the individual reports being purchased separately:
-Cancer Diagnostic Testing World Markets.- Cardiac Marker Diagnostic Testing Markets.- Companion Diagnostics in Personalized Medicine and Cancer Therapy.- European Point of Care Diagnostic Testing Markets.- High-Growth Diagnostic Testing Markets.- Key Diagnostic Testing Markets.- Molecular Diagnostics in Cancer Testing.- Molecular Diagnostics in
5/2/16 - Acerus Acquires Canadian Rights to GYNOFLOR?
By a News Reporter-Staff News Editor at Clinical Trials Week Acerus Pharmaceuticals Corporation announced that it has entered into a license and supply agreement with Medinova AG, a Swiss pharmaceutical company, granting Acerus the exclusive rights to commercialize GYNOFLOR? in Canada. Currently, there are no approved products in Canada contain
5/2/16 - Acura Pharmaceuticals Announces First Quarter 2016 Financial Results
Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the first quarter ended March 31, 2016. The Company reported net loss of $3.4 million for the first quarter 2016 or $0.28 per diluted share, compared to net income of $1.2 million or $0.13 per diluted share for the
5/2/16 - ACURA PHARMACEUTICALS, INC - 10-Q - Management's Discussion and Analysis of Financial Condition and Results of Operations
This discussion and analysis should be read in conjunction with the Company's financial statements and accompanying notes included elsewhere in this Report. Historical operating results are not necessarily indicative of results in future periods. Forward-Looking Statements Certain statements in this Report constitute "forward-looking statements"...
5/2/16 - Allergan Receives FDA Approval and Launches First Generic Version of CRESTOR (rosuvastatin)
Allergan plc, a leading global pharmaceutical company, today confirmed that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for rosuvastatin calcium 5, 10, 20 and 40 mg tablets, the generic version of AstraZeneca's CRESTOR tablets. Following receipt of the FDA approval, Allergan
5/2/16 - Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
DEERFIELD, Ill. and OSAKA, Japan, May 2, 2016/ PRNewswire/ Takeda Pharmaceuticals U.S.A., Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited, and Lundbeck announced today that Brintellix will be marketed in the United States under the new name Trintellix starting in June of 2016. It's still the same medication, dosing and ex
5/2/16 - Delavau Announces Pharmaceutical Business Name Change
For over 150 years, Delavau has served as a partner to leading over-the-counter and vitamin-mineral-supplement brands offering full turnkey contract manufacturing services. As a contract manufacturer of calcium-based vitamins, minerals, supplements, and over-the-counter products, Delavau Pharmaceutical Partners produces a variety of tablets with...
5/2/16 - Expert: Get to know your vet to make antibiotic transition easier
If the FDA catches a producer misusing feed grade and water soluble antibiotics the producer will be fined and prosecuted. In addition, the FDA will declare the livestock as adulterated foodstuffs and the value of that livestock "goes to nothing." "The FDA fine and challenges you may deal with them over are nothing compared to the value you lose w
5/2/16 - Flamel Technologies Receives FDA Approval of Akovaz(TM)
Flamel obtained NDA approval for Akovaz as scheduled on April 29 and is the first to receive approval from the FDA for ephedrine sulfate. Our ?clat portfolio of products, which includes Bloxiverz and Vaculep , has produced significant cash flow for Flamel, allowing us to operate independently of partners, fund strategic acquisitions and conti
5/2/16 - Flamel Technologies to Report First Quarter 2016 Results
Flamel Technologies today announced that the Company will report its financial results for the first quarter ended March 31, 2016 on Monday, May 9, 2016, before the market open. A replay of the webcast will be archived on Flamel's website for 90 days following the event. About Flamel Technologies: Flamel Technologies SA is a specialty pharmaceutica
5/2/16 - Orexigen Announces South Korean Approval of Contrave (naltrexone HCI and bupropion HCI Extended-Release) Monotherapy for Weight Management in Overweight or Obese Adult Patients
Orexigen Therapeutics, Inc. today announced that the Korean Ministry of Food and Drug Safety has approved Contrave monotherapy for weight management in overweight or obese adult patients. In anticipation of a commercial launch this quarter, Orexigen has shipped an initial order of Contrave tablets to Kwang Dong Pharmaceutical Company, Ltd., th
5/2/16 - Perrigo Announces FDA Approval and Launch of the Generic Version of BenzaClin Pump Topical Gel
Perrigo Company plc today announced it has received final U.S. Food and Drug Administration approval for the generic version of Valeant Pharmaceutical International, Inc.' s BenzaClin Pump Topical Gel. Perrigo' s Chief Executive Officer John T. Hendrickson stated, "This Rx product approval and launch demonstrates the team's ability to leverage
The following discussion and analysis should be read in conjunction with the financial statements and notes thereto appearing elsewhere herein. We are a development stage company that intends to acquire a series of businesses which specialize in compounding pharmacy activities, largely direct to consumers, and to doctors and veterinary professional
5/2/16 - Vanc Pharmaceuticals Announces Launch of New OTC Product and Provides Update on Sales Force Ramp Up
Vanc Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter markets, is pleased to announce that Health Canada has approved Cortivera?- H, a premium topical product for minor skin irritations. Cortivera?- H, a made in Canada product, contains 1% hydrocortisone cream for the treatment of minor sk
4/29/16 - Allergan Receives CHMP Positive Opinion For ENZEPI (Pancrelipase) For Patients With Exocrine Pancreatic Insufficiency (EPI)
Allergan plc, a leading global pharmaceutical company, today announced that the Committee for Medicinal Products for Human Use has adopted a Positive Opinion for the Marketing Authorisation of ENZEPI in the European Union. 1 ENZEPI is a pancreatic enzyme replacement therapy for patients with exocrine pancreatic insufficiency due to cystic f
Articles(s): 1 - 25 of 27     Next >>     Go To Page:

© 2016 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry


Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
Pharmacy Spanish
This lesson is supported by:
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...

Websites »
Copyright © 2009 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement